New nitric oxide-releasing polymers for implantable devices

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 11, 2007, Pages 1397-1400

  Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Coronary artery disease; Immunosuppressants; Nitric oxide; PTCA; Restenosis; Thrombosis; Tissue remodelling

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ESTROGEN; NITRIC OXIDE; POLYETHYLENEIMINE; POLYMER; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; DRUG STABILITY; MEDICAL INSTRUMENTATION; PATENT; THROMBOSIS; VASCULAR DISEASE;

EID: 36549023507     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.11.1397     Document Type: Article

References (19)

1. SERRUYS PW, KUTRYK MJB, ONG ATL: Coronary artery stents. N. Engl. J. Med. (2006) 354:483-495.
2. VAINA S, SERRUYS PW: Progressive stent technologies: new approaches for the treatment of cardiovascular diseases. Expert Opin. Drug Deliv. (2006) 3(6):783-797.
3. KRUCOFF MW, BOAM A, SCHULTZ DG: Drug-eluting stents 'deliver heartburn': how do we spell relief going forward? Circulation (2007) 115:2990-2994.
4. SCHUCHMAN M: Debating the risk of drug-eluting stenting. N. Engl. J. Med. (2007) 356:325-327.
5. LOWE R, MENOWN IB, NOGAREDA G, PENN IM: Coronary stents: in these days of climate change should all stents wear coats? Heart (2005) 91:iii20-iii23.
6. LIN CE, JANERO DR, GARVEY DS: Nitric-oxide-based molecular strategies for restenosis therapy. Expert Opin. Ther. Patents (2005) 15(5):483-495.
7. WEISZ G, LEON MB, HOLMES DR Jr et al.: Two-year outcomes after sirolimus-eluting stent implantation: results from the sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J. Am. Coll. Cardiol. (2006) 47:1350-1355.
8. FARB A, BOAM AB: Stent thrombosis redux-the FDA perspective. N. Engl. J. Med. (2007) 356:984-987.
9. MONCADA S, PALMER RMJ, HIGGS EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. (1991) 43:109-142.
10. MEGSON IL, WEBB DJ: Nitric oxide donor drugs: current status and future trends. Expert Opin. Investig. Drugs (2002) 11(5):587-601.
11. SCATENA R, BOTTONI P, MARTORANA GE, GIARDINA B: Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin. Investig. Drugs (2005) 14(7):835-846.
12. FROST MC, REYNOLDS MM, MEYERHOFF ME: Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials (2005) 26:1685-1693.
13. HOMER KL, WANSTALL JC: Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. Br. J. Pharmacol. (2002) 137:1071-1081.
14. REYNOLDS MM, FROST MC, MEYERHOFF ME: Nitric oxide-releasing hydrophobic polymers: preparation, characterization, and potential biomedical applications. Free Radic. Biol. Med. (2004) 1:926-936.
15. ZHANG H, ANNICH GM, MISKULIN J et al.: Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and in vivo evaluation. Biomaterials (2002) 23:1485-1494.
16. BAEK SH, HRABIE JA, KEEFER LK et al.: Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation (2002) 105:2779-2784.
17. TIERNEY TS, CLATTERBUCK RE, LAWSON C, THAI QA, RHINES LD, TAMARGO RJ: Prevention and reversal of experimental posthemorrhagic vasospasm by the periadventitial administration of nitric oxide from a controlled-release polymer. Neurosurgery (2001) 49:945-951.
18. NABLO BJ, SCHOENFISCH MH: Antibacterial properties of nitric oxide-releasing sol-gels. J. Biomed. Mater. Res. A (2003) 15:1276-1283.
19. KEEFER LK: Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates. Ann. Rev. Pharmacol. Toxicol. (2003) 43:585-607.